Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

733
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
733
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

661
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
661
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

615
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
615
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

740
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
740
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.3K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.3K
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

449
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
449

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Circulating gut microbial metabolites and risk of coronary heart disease: A prospective multi-stage metabolomics study.

PLoS medicine·2026
Same author

Initiating Preventive Care for Hyperlipidemia in the Emergency Department: The Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial.

Critical pathways in cardiology·2025
Same author

Circulating gut microbial metabolites and risk of coronary heart disease: a prospective, multi-stage study.

medRxiv : the preprint server for health sciences·2025
Same author

Enhanced negative modulation of urotensin II on cardiac function and [Ca<sup>2+</sup>]<sub>i</sub> regulation in a diabetic rat model: Insights into molecular and cellular mechanisms.

The Journal of pharmacology and experimental therapeutics·2025
Same author

iDDN: determining trans-omics network structure and rewiring with integrative differential dependency networks.

Bioinformatics advances·2025
Same author

Genome-wide association study and multi-ancestry meta-analysis identify common variants associated with carotid artery intima-media thickness.

medRxiv : the preprint server for health sciences·2025

Related Experiment Video

Updated: Mar 23, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in G&#246;ttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.2K

C-Type Natriuretic Peptide Improves Left Ventricular Functional Performance at Rest and Restores Normal Exercise

Tiankai Li1, Heng-Jie Cheng1, Nobuyuki Ohte1

  • 1Wake Forest School of Medicine, Winston-Salem, North Carolina (H.J.C., N.O., H.H., A.M., D.M.H., W.C.L., C.P.C.), and the First Affiliated Hospital of Harbin Medical University, Harbin, China (T.L., H.J.C, W.L., C.P.C).

The Journal of Pharmacology and Experimental Therapeutics
|March 31, 2016
PubMed
Summary

C-type natriuretic peptide (CNP) improves heart function in heart failure (HF) by enhancing left ventricular (LV) performance and arterial coupling. CNP treatment restores normal exercise responses in HF dogs, improving overall cardiac efficiency.

More Related Videos

Myocardial Infarction and Functional Outcome Assessment in Pigs
12:03

Myocardial Infarction and Functional Outcome Assessment in Pigs

Published on: April 25, 2014

28.8K
Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury
07:23

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury

Published on: March 7, 2022

7.5K

Related Experiment Videos

Last Updated: Mar 23, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in G&#246;ttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.2K
Myocardial Infarction and Functional Outcome Assessment in Pigs
12:03

Myocardial Infarction and Functional Outcome Assessment in Pigs

Published on: April 25, 2014

28.8K
Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury
07:23

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury

Published on: March 7, 2022

7.5K

Area of Science:

  • Cardiovascular Physiology
  • Pharmacology

Background:

  • Heart failure (HF) impairs left ventricular (LV) arterial coupling and diastolic function, worsening during exercise.
  • C-type natriuretic peptide (CNP) levels are elevated in HF, but its functional role remains unclear.

Purpose of the Study:

  • To investigate the effects of CNP on exercise-induced cardiac dysfunction in a canine model of heart failure.
  • To test if CNP's vasodilating, natriuretic, and inotropic/lusitropic properties can prevent abnormal exercise responses in HF.

Main Methods:

  • Pacing-induced heart failure was created in 10 dogs.
  • CNP was administered intravenously (2 μg/kg + 0.4 μg/kg/min for 20 min).
  • Left ventricular (LV) dynamics and plasma cGMP levels were measured at rest and during exercise before and after HF, with and without CNP treatment.

Main Results:

  • CNP infusion significantly increased plasma cGMP levels post-HF.
  • At rest, CNP reduced LV end-systolic pressure, arterial elastance, and improved LV contractility, relaxation, and filling.
  • During exercise, CNP attenuated increases in LV pressure, improved relaxation and contractility, enhanced LV-arterial coupling, and increased LV mechanical efficiency.

Conclusions:

  • Exogenous CNP improves LV performance at rest by causing arterial vasodilation and augmenting LV contraction, relaxation, and filling.
  • CNP treatment restores normal exercise responses in HF by improving LV-arterial coupling and overall cardiac efficiency.